A pharma-sponsored unplanned secondary analysis of the phase 3 LATITUDE trial establishing the efficacy of adding abiraterone to ADT for metastatic castrate sensitive prostate cancer demonstrates the one-fifth of enrollees who received a bone-modifying agent such as a bisphosphonate or denosumab had a significantly longer time to skeletal-related events. With that said, prophylactic radiation!https://quadshotnews.com/a-gray-of-prevention/
to high-risk bone mets may become a cheaper and safer option in many cases. | Fukuokaya, JAMA Netw Open 2024
to high-risk bone mets may become a cheaper and safer option in many cases. | Fukuokaya, JAMA Netw Open 2024